Navigation Links
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Date:9/21/2010

230 targets multiple subtypes of the receptor for somatostatin (sst), a hormone that controls the pituitary gland. Its highest affinity is to sst5, a receptor subtype frequently expressed by the pituitary tumors associated with Cushing's disease. Currently approved somatostatin analogs preferentially bind to sst2 and are not effective in Cushing's disease(6).

SOM230 is currently being studied as a twice-daily sc injection, as well as a long-acting release (LAR) once-monthly intramuscular injection for the treatment of multiple disease types, including Cushing's disease, carcinoid syndrome and acromegaly(10).

Because it is an investigational compound, the safety and efficacy profile of SOM230 has not yet been established. Access to this investigational compound is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. There is no guarantee that SOM230 will become commercially available(6).

Information about Novartis clinical trials for SOM230 can be obtained by healthcare professionals at www.pasporttrials.com.

DisclaimerThe foregoing release contains forward-looking statements that can be identified by terminology such as "will," "planned," "potential," or similar expressions, or by express or implied discussions regarding regulatory submissions or approvals for SOM230, or the timing of such submissions or approvals, or regarding potential future revenues from SOM230. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with SOM230 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guar
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... NEW YORK , July 30, 2015 ... releases a new research report with market ... size, share, forecast, porter analysis, recent developments, ... Global Industry Insight: Biosensors Market ...      (Logo: http://photos.prnewswire.com/prnh/20150727/756778 ) ...
(Date:7/30/2015)... AUSTIN, Texas , July 30, 2015 ... solutions company focused on gynecologic disease, announced ... 2015 financial results after the market close ... an investor conference call and webcast at ... August 13, 2015 at 4:30pm Eastern/1:30pm Pacific  ...
(Date:7/30/2015)... 30, 2015 What can be ... areas are going to grow at the fastest rates? ... revenues to 2025, assessing data, trends, opportunities and prospects ... 176 tables, charts, and graphs. Discover the most lucrative ... Our new study lets you assess forecasted sales at ...
Breaking Medicine Technology:Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
(Date:7/31/2015)... St. Louis, MO (PRWEB) , ... July 31, 2015 , ... ... litigation* currently underway in U.S. District Court in the Northern District of Illinois, Androgel ... documents. On Monday, July 20, a docket entry was made recording the minutes of ...
(Date:7/31/2015)... ... July 31, 2015 , ... People ... when purchasing disability insurance, where price is an important factor to clients when ... leading insurance carrier, offers the Preferred Producer Multi-Life Discount program, where advisers pass ...
(Date:7/30/2015)... VA (PRWEB) , ... July 31, 2015 , ... ... Floor:, Reduce Errors By 50% or More, **Presented by FDAnews and Ginette M. ... Ginette Collazo, a 15 year veteran of helping drug, biologic and device firms ...
(Date:7/30/2015)... Sierra Madre, CA (PRWEB) , ... July 30, 2015 , ... ... wound care programs, the activity of recruiting patients becomes a serious challenge. Because of ... wound care program to patients within the local community. , The team at ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... program entitled " Lovetraction Lines ." It's for women interested in improving their ... they desire. The course, which officially launched to the public early this morning, ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:Secura Consultants Gives Advisers Competitive New Edge with Multi-Life Discount Program 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2
... ... bomb is to explode in the coming years , ... London, UK (PRWEB) June 13, 2009 -- New images released by Lloydspharmacy show how ... affects around a quarter of the UK population, one of the highest prevalence rates for hayfever ...
... Calif., June 12 An independent factfinder jointly hired by Fresno ... County,s plan to cut the wages and benefits of 10,000 home ... and ordered that the cuts be halted. The Fresno Board of ... Tuesday. , , SEIU UHW invoked their right to arbitration ...
... Customs Enforcement Slow to Act, Not Doing Enough to Protect Employees, ... and Customs Enforcement Krome Service Processing Center in Miami, FL has ... has urged the agency for weeks to fit its personnel with ... with the H1N1 virus. "This is an outrage that it ...
... Ill., June 12 The American College of Chest ... historic 79-17 vote yesterday and the U.S. House of ... Food and Drug Administration meaningful authority to regulate tobacco ... represents the strongest legislation Congress has ever passed to ...
... says , FRIDAY, June 12 (HealthDay News) -- Here,s more ... about 4 percent of males develop dry eye disease, making ... for seeing an eye doctor in the United States, researchers ... or burning sensation in the eyes, according to the North ...
... ... largest online retailer of vision care products, unveils the newest addition to its collection ... organic, recycled material making them an environmentally friendly choice. , ... Vancouver, BC (PRWEB) - Clearly Contacts, the ...
Cached Medicine News:Health News:Lloydspharmacy Reveals Hayfever Misery to Hit One in Two People by 2060 2Health News:Lloydspharmacy Reveals Hayfever Misery to Hit One in Two People by 2060 3Health News:Neutral Factfinder Rules That Fresno County Home Care Wage Cuts Should Be Stopped 2Health News:Krome Immigration Service Processing Center Has Confirmed H1N1 Flu Cases 2Health News:American College of Chest Physicians Celebrates the Nation's Victory for Tobacco Control 2Health News:For Men Over 50, Odds of Eye Discomfort Increases 2Health News:Clearly Contacts Goes Green With Organic Glasses 2
Inquire...
Power Supply E865 is ideal for electrophoresis and semi-dry blotting applications. The electrical leads from Hoefer Gel apparatus are fully compatible with this new E865 power supply and there is no ...
Inquire...
... Scientific PSE Power Supply . The digital ... V and 2 A in 1 volt and ... run up to three SEA 2000® apparatus simultaneously ... preset and actual values of voltage, current and ...
Medicine Products: